Ulgu Mustafa Mahir, Birinci Suayip
Acting Director-General at Ministry of Health of Turkiye, Ankara, Turkiye.
Vice-Minister at Ministry of Health of Turkiye, Ankara, Turkiye.
North Clin Istanb. 2023 Aug 4;10(4):501-506. doi: 10.14744/nci.2023.59908. eCollection 2023.
The aim of this study was to investigate the utilization patterns and clinical implications of cancer antigen 125 (CA-125) testing in the diagnosis of ovarian and endometrial cancers using a large-scale dataset obtained from the Ministry of Health.
A retrospective analysis was conducted on anonymized data collected between 2017 and 2021, comprising 3.917.240 individuals who underwent CA-125 testing. The data included demographic information, test results, diagnoses, and clinical characteristics. Descriptive statistics and comparative analyses were performed to assess the utilization trends and clinical outcomes associated with CA-125 testing.
Among the study population, CA-125 testing was primarily requested for female individuals, with the highest number of tests performed in the age group of 18-64 years. The overall positive rate for CA-125 was 13.31%, with slightly lower rates observed in females (13.18%) than males (14.07%). The study identified a significant association between elevated CA-125 levels and cancer diagnoses, with 19.88% of positive CA-125 results indicating cancer, whereas 10.51% had no cancer diagnosis. Furthermore, the study revealed a higher likelihood of cancer detection among individuals aged 65 years and above, with a positive rate of 17.79%.
Our findings provide valuable insights into the utilization patterns and clinical implications of CA-125 testing in ovarian and endometrial cancer diagnosis. While CA-125 remains a prominent tumor marker, its interpretation should consider age, gender, and clinical context. The study emphasizes the potential benefits of integrating additional markers and imaging modalities to enhance diagnostic accuracy. These findings contribute to optimizing the use of CA-125 testing for early detection and management of gynecological malignancies, thereby improving patient outcomes.
本研究旨在利用从卫生部获取的大规模数据集，调查癌抗原125（CA-125）检测在卵巢癌和子宫内膜癌诊断中的应用模式及临床意义。
对2017年至2021年期间收集的匿名数据进行回顾性分析，数据来自3917240名接受CA-125检测的个体。数据包括人口统计学信息、检测结果、诊断及临床特征。进行描述性统计和比较分析，以评估与CA-125检测相关的应用趋势和临床结果。
在研究人群中，CA-125检测主要针对女性个体，18 - 64岁年龄组检测次数最多。CA-125的总体阳性率为13.31%，女性（13.18%）略低于男性（14.07%）。研究发现CA-125水平升高与癌症诊断之间存在显著关联，19.88%的CA-125阳性结果表明患有癌症，而10.51%的结果未诊断出癌症。此外，研究显示65岁及以上个体癌症检测的可能性更高，阳性率为17.79%。
我们的研究结果为CA-125检测在卵巢癌和子宫内膜癌诊断中的应用模式及临床意义提供了有价值的见解。虽然CA-125仍然是一种重要的肿瘤标志物，但其解读应考虑年龄、性别和临床背景。该研究强调了整合其他标志物和影像学检查手段以提高诊断准确性的潜在益处。这些发现有助于优化CA-125检测在妇科恶性肿瘤早期检测和管理中的应用，从而改善患者预后。
